Medical news today: Monday, November 16, 2026
Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
Get tomorrow's issue in your inbox.
- 01
Apple and OpenEvidence open a US study app for AI answers to health questions
Source: TechCrunch
Apple has launched a research app with OpenEvidence that gives simplified answers to everyday medical questions grounded in sources such as NEJM, JAMA and Nature, TechCrunch reports. It is open to US adults over 21 with an iPhone 15 or later and aims for up to 200,000 participants over more than 12 months; Apple says data is anonymised and not used to train AI models.
Why it mattersFree, source-backed AI answers could help people prepare for appointments and avoid paying for unnecessary visits, but they are not a diagnosis. Concerning symptoms still need a clinician. More on Journal papers →
- 02
Tirzepatide cuts BMI by 18.5% in teenagers with obesity in a Phase 3 trial
Source: MedPage Today
In the Phase 3 SURMOUNT-ADOLESCENTS trial of 160 adolescents aged 12 to under 18, weekly tirzepatide (Zepbound) plus lifestyle support reduced BMI by 18.5% on average at 72 weeks versus a 0.5% rise on placebo, MedPage Today reports; results were presented at ObesityWeek and published in JAMA. Gastrointestinal side effects were common (81.5% vs 54.9%), and 9.3% stopped treatment because of side effects.
Why it mattersThe results could lead to an approval for teenagers, which would shape whether insurers and health systems pay for these costly drugs for young people. Editorialists warn against copying the trial's dosing in routine care; decisions belong with a child's doctor. More on Approvals & regulatory →
- 03
Congo's Ebola outbreak passes 11,000 cases and spreads to Nigeria, Kenya and Uganda
Source: Medical Xpress (AP)
Six months after it was declared, Congo's Ebola outbreak has recorded more than 11,000 cases, with nearly half of those infected dying, according to government data cited by AP. Africa CDC says 80% of new cases are detected outside surveillance and has raised concerns about more than $700 million in aid that remains unaccounted for; Nigeria, Kenya and Uganda have confirmed cases.
Why it mattersUnpaid health workers and missing aid money are slowing the response, which raises costs for every country in the region. Travellers and businesses with links to affected areas should follow official travel-health guidance. More on Approvals & regulatory →
- 04
FDA rejects Summit's ivonescimab lung cancer filing after survival endpoint falls short
Source: Summit Therapeutics
Company-reported: Summit Therapeutics announced on November 15 that the FDA issued a Complete Response Letter for ivonescimab plus platinum-containing chemotherapy in previously treated EGFR-mutated locally advanced or metastatic non-squamous non-small-cell lung cancer. In its summary of the letter, the company says the FDA considered the application insufficient because the Phase III HARMONi study did not show a statistically significant overall-survival improvement, despite meeting its progression-free-survival endpoint. The FDA letter itself was not posted with the company announcement, so the regulator's rationale here is reported through the sponsor.
Why it mattersA 'complete response letter' means the FDA will not approve the drug as filed, so US patients with this lung cancer will not get it soon and investors in the company take the hit. It applies to this filing only, not to ivonescimab's other trials. More on Approvals & regulatory →
Market news · Not investment advice
- 05
US flu season starts unusually early, with high activity in seven states
Source: MedPage Today (AP)
The CDC reported high flu activity in seven states last week, up from two the week before, and more than 3% of doctor visits were for flu-like illness, according to an Associated Press report carried by MedPage Today. The CDC estimates at least 2.6 million illnesses, 36,000 hospitalisations and 2,100 deaths so far this season; most cases are an H1N1 strain that early data suggest the current vaccine can recognise.
Why it mattersAn early season means more sick days and lost wages before the holidays; flu shots are often low-cost or covered by insurance, so checking now can save money later. Readers outside the US should follow their own health authority's advice. More on Drug & device safety →
- 06
EMA committee backs seven new medicines, including two insulin biosimilars
Source: European Medicines Agency
The EMA's Committee for Medicinal Products for Human Use reported seven positive opinions on new medicines at its November meeting, including recommendations for aumolertinib, baxdrostat and sintilimab, plus two insulin-aspart biosimilars and two generic medicines. The committee also recommended 11 extensions of therapeutic indications. These are CHMP opinions and recommendations; the European Commission must still issue the final marketing-authorisation decisions.
Why it mattersBiosimilars and generics, cheaper versions of existing medicines, tend to push prices down once they launch, which matters to anyone paying for insulin. These are recommendations; the European Commission still has to give final approval. More on Approvals & regulatory →
- 07
EMA flags that tirzepatide may make the contraceptive pill less reliable
Source: European Medicines Agency
The EMA says CHMP adopted a direct healthcare professional communication about the potential effect of Mounjaro (tirzepatide) on oral-contraceptive reliability. The communication advises adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase, or switching to a non-oral contraceptive method. The agency notes that information on the effect on oral-contraceptive pharmacokinetics and efficacy is limited; dissemination is to follow a European Commission decision.
Why it mattersPeople using Mounjaro (tirzepatide) for diabetes or weight loss together with the pill may need a backup method at certain times, which can mean an extra cost and a conversation with a doctor or pharmacist. Do not change any medicine without professional advice. More on Approvals & regulatory →
- 08
FDA: 'Candy Power For Man' honey supplement recalled for hidden tadalafil
Source: The Hill
Eros Apothecary is recalling its Candy Power For Man Organic Honey after FDA laboratory testing found undeclared tadalafil, the active ingredient in the prescription drug Cialis, according to an FDA notice reported by The Hill. The product was sold on eBay between April 27 and July 20 in yellow and orange packaging.
Why it matters'Natural' sexual-enhancement products bought online can hide prescription drugs that interact dangerously with heart medicines called nitrates, so the money saved is not worth the risk. The FDA advises stopping use and talking to a healthcare provider if you have health problems after using it. More on Approvals & regulatory →
- 09
Gen Z shoppers trust dermatologists most but still buy skincare from social media
Source: Cosmetics Business
A survey by tele-dermatology company Curology of nearly 2,000 skincare buyers aged 13 to 29 found 43% named dermatologists as their most trusted source versus 9% for social media, Cosmetics Business reports. Yet 62% still turn to social media for advice and 65% bought a product based on a social recommendation in the past six months. The survey was run by a company that sells dermatology services.
Why it mattersBuying products because they trend online can waste money on items that do not suit your skin; a check against expert sources first can save repeat purchases. The survey is company-commissioned. More on Cosmetics & skincare →
- 10
Adding camrelizumab before head-and-neck cancer surgery improves two-year results in a Phase 2 trial
Source: JAMA Oncology
A multicentre Phase 2 randomised trial involving 125 patients at four academic hospitals in China compared perioperative camrelizumab plus chemotherapy followed by surgery and adjuvant treatment with standard surgery-based treatment for resectable locally advanced head-and-neck squamous-cell carcinoma. The reported two-year event-free-survival rates were 77.8% and 46.1%, respectively (hazard ratio 0.34; P=.001). Grade 3 or higher treatment-emergent adverse events occurred in 79.4% of the combination group and 56.5% of controls. The investigators say the findings warrant confirmation in a Phase 3 trial.
Why it mattersIf confirmed in a larger trial, this approach could change how this cancer is treated, but it also caused more serious side effects; for now it is early evidence, not a standard treatment to ask for. More on Drug & device safety →
- 11
Blackstone puts up to $1.5 billion into Pfizer's monthly obesity shot
Source: BioPharma Dive
Markets: Blackstone Life Sciences will invest up to $1.5 billion to fund as many as 10 Phase 3 trials of berobenatide, a potentially once-monthly GLP-1 obesity injection Pfizer gained through its $10 billion Metsera acquisition, BioPharma Dive reports. Pfizer will pay Blackstone milestones if the FDA approves the drug and sales goals are hit.
Why it mattersMore competition among weight-loss drugs is one of the main forces that could bring prices down for patients and insurers over time, and it shows how private-equity money now funds big drug trials. Not investment advice. More on Approvals & regulatory →
Market news · Not investment advice
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
- Wednesday, November 11, 2026FDA approves pimicotinib; GLP-1 eye warning and two device alerts; WHO updates TB resistance catalogue
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
